Takara Bio Offers Drug for Treatment of Chronic Lymphatic Leukemia.Tokyo, Japan, Sept 7, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Takara Bio Inc., a forerunner in cancer treatment, has offered its RetroNectin for the treatment chronic lymphatic leukemia lymphatic leukemia n. See lymphocytic leukemia. in phase-I clinical trials currently being conducted at the U.S. Memorial Sloan-Kettering Cancer Center The Memorial Sloan-Kettering Cancer Center (MSKCC) in New York City is a cancer treatment and research institution founded in 1884 as the New York Cancer Hospital. The main campus is located at 1275 York Avenue, between 67th and 68th Streets, with other locations in New (MSKCC MSKCC Memorial Sloan-Kettering Cancer Center ). The clinical trial targets 30 patients and will take about two to three years to complete. This new approach of gene treatment using RetroNectin has been performed in 40 institutions around the world. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion